Product Name: Remdesivir
CAS No.: 1809249-37-3
Molecular Formula: C27H35N6O8P

Remdesivir is a nucleoside analogue and is an RNA-dependent RNA polymerase (RdRp) inhibitor. It can synthesize anti-virus by inhibiting viral nucleic acid. The current bed study for Ebola virus infection has reached stage II. Mice infected with MERS performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that remdesivir has a certain effect on the inhibition of new coronavirus.

Remdesivir is an antiviral drug developed by Gilead Sciences to treat the novel coronavirus (COVID-19). It is the only antiviral drug that has been approved by the United States Food and Drug Administration (FDA) to treat COVID-19. Remdesivir works by blocking the virus from replicating in the body, thus helping to reduce the severity of the disease and shorten the time required for recovery. In clinical trials, Remdesivir was shown to significantly reduce recovery time for hospitalized patients suffering from COVID-19.

Administration:
- Administered intravenously
- Can be used in both adults and children
- Generally used in combination with other treatments, such as oxygen therapy

Safety & Efficacy:
- Safety and efficacy established in numerous clinical trials
- Found to be safe and effective for the treatment of COVID-19
- Important tool in the fight against the novel coronavirus
- Helps reduce duration of hospitalization and improve chances of recovery

This is a pharmaceutical-grade API for the treatment of viral infections including COVID-19.